Pharmacokinetic assessment of the uptake of 16β-18F-fluoro- 5α-dihydrotestosterone (FDHT) in prostate tumors as measured by PET

Journal of Nuclear Medicine

Volumn 51, Issue 2, 2010, Pages 183-192

  Beattie, Bradley J ^a   Smith Jones, Peter M ^a   Jhanwar, Yuliya S ^b   Schöder, Heiko ^a   Ross Schmidtlein, C ^a   Morris, Michael J ^a   Zanzonico, Pat ^a   Squire, Olivia ^a   Meirelles, Gustavo S P ^c   Finn, Ron ^a   Namavari, Mohammad ^d   Cai, Shangde ^a   Scher, Howard I ^a   Larson, Steven M ^a   Humm, John L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Dynamic PET; FDHT; Molecular imaging; PET CT; Pharmacokinetic modeling; Prostate cancer; Radiotracer tissue kinetics

Indexed keywords

16BETA FLUORO 5ALPHA DIHYDROTESTOSTERONE F 18; ABIRATERONE; ANDROGEN RECEPTOR; BICALUTAMIDE; DOCETAXEL; FLUOROURACIL; OXALIPLATIN; RADIOPHARMACEUTICAL AGENT; TANESPIMYCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CORRELATIONAL STUDY; DRUG BINDING; DRUG HALF LIFE; DRUG UPTAKE; HEART; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; METABOLITE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYSTEMATIC REVIEW; VALIDATION STUDY; VEIN BLOOD FLOW;

AGED; COHORT STUDIES; DIHYDROTESTOSTERONE; FLUORINE RADIOISOTOPES; HEART; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, ANDROGEN;

EID: 75749116783     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.066159     Document Type: Article

References (8)

1. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008;8:440-448.
2. 18F]fluoro-19-nor-5 α-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution. J Med Chem. 1995;38:816-825.
3. Bonasera TA, Oneil JP, Xu M, et al. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J Nucl Med. 1996;37:1009-1015.
4. Dehdashti F, Picus J,Michalski JM, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging. 2005;32:344-350.
5. 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004;45:366-373.
6. 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J Nucl Med. 2004;45:1966-1971.
7. Schwartz G. Estimating dimension of a model. Ann Stat. 1978;6:461-464.
8. Fedoruk MN, Gimenez-Bonafe P, Guns ES, Mayer LD, Nelson CC. P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate. 2004;59:77-90.